KR20230035522A - 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존 - Google Patents

폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존 Download PDF

Info

Publication number
KR20230035522A
KR20230035522A KR1020227042096A KR20227042096A KR20230035522A KR 20230035522 A KR20230035522 A KR 20230035522A KR 1020227042096 A KR1020227042096 A KR 1020227042096A KR 20227042096 A KR20227042096 A KR 20227042096A KR 20230035522 A KR20230035522 A KR 20230035522A
Authority
KR
South Korea
Prior art keywords
dione
phenyl
methyl
ethoxy
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020227042096A
Other languages
English (en)
Korean (ko)
Inventor
페데몬테 마크 마르티넬
랄란자 마리아 필라 피즈쿠에타
사우라 안나 빌랄타
로페즈 에스테파니아 트래버
폴리 소니아 마리아
유제로스 누리아 이즈퀴에르도
Original Assignee
미노릭스 테라퓨틱스 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미노릭스 테라퓨틱스 에스.엘. filed Critical 미노릭스 테라퓨틱스 에스.엘.
Publication of KR20230035522A publication Critical patent/KR20230035522A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227042096A 2020-04-30 2021-04-30 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존 Abandoned KR20230035522A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
KR20230035522A true KR20230035522A (ko) 2023-03-14

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042096A Abandoned KR20230035522A (ko) 2020-04-30 2021-04-30 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존

Country Status (11)

Country Link
US (1) US20230172921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142720A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525981A (cg-RX-API-DMAC7.html)
KR (1) KR20230035522A (cg-RX-API-DMAC7.html)
CN (1) CN116390725A (cg-RX-API-DMAC7.html)
AU (1) AU2021265345A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180351A1 (cg-RX-API-DMAC7.html)
IL (1) IL297771A (cg-RX-API-DMAC7.html)
MX (1) MX2022013021A (cg-RX-API-DMAC7.html)
WO (1) WO2021220250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
JP2026500743A (ja) * 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20120190637A1 (en) * 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
EP4142720A1 (en) 2023-03-08
CN116390725A (zh) 2023-07-04
US20230172921A1 (en) 2023-06-08
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
CA3180351A1 (en) 2021-11-04
BR112022021951A2 (pt) 2022-12-13
AU2021265345A1 (en) 2022-12-08
JP2023525981A (ja) 2023-06-20
WO2021220250A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20230241014A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20230157994A1 (en) New compositions and methods of treating covid-19 disease
US20230172921A1 (en) Leriglitazone for treating lung inflammation and interstitial lung disease
US20260041660A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
ES2935834T3 (es) Métodos para tratar enfermedad de inmunodeficiencia
US20220288155A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
JP2023517220A (ja) 微生物感染症の治療のためのnk細胞およびそれらの使用
JP2023512062A (ja) 関節の炎症を治療するためにモメロチニブを使用する方法
HK40096631A (en) Leriglitazone for treating lung inflammation and interstitial lung disease
EP4115885A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
CN116096364A (zh) 扩散增强化合物用于治疗病毒和细菌诱导的呼吸道疾病的应用
US20230302009A1 (en) Bace1 inhibitor treatment for suppressing cytokine storm
US20220017614A1 (en) Anti-IL6 Agent for Treating Coronavirus Infection
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
RU2837859C1 (ru) Лечение коронавирусной инфекции
Arish et al. Targeting a macrophage stemness factor to mitigate diseases post respiratory viral infection
Ramezaninejad et al. The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
Farne The prostaglandin D2 pathway in rhinovirus-induced asthma exacerbations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240430

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration